v3.26.1
RESEARCH, DEVELOPMENT, AND CLINICAL TRIAL EXPENSES, NET
 9 Months Ended
Apr. 30, 2026
Research and Development [Abstract]  
RESEARCH, DEVELOPMENT, AND CLINICAL TRIAL EXPENSES, NET

NOTE 9: RESEARCH, DEVELOPMENT, AND CLINICAL TRIAL EXPENSES, NET

 

(i)

On August 25, 2025, the Company announced that it had been awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (“NCI”) to support the advancement of Bria-PROS+™ for the treatment of prostate cancer. The grant provides non-dilutive funding intended to support manufacturing activities and planned clinical evaluation of the program.

 

The grant reimburses certain qualifying research and development expenditures incurred by the Company in connection with the program. In accordance with the Company’s accounting policy for government assistance, amounts received under the grant are recognized as a reduction of research and development expenses in the period in which the related costs are incurred.

 

During the three and nine months ended April 30, 2026, the Company received $110,205 and $936,363, respectively, under the SBIR grant and recorded this amount as a reduction of research and development expenses in the condensed consolidated statements of operations.

 

As of April 30, 2026, the Company may receive up to an additional $1.1 million under the grant, subject to the achievement of certain research objectives and compliance with the grant terms.